Post-Traumatic Stress Disorder Clinical Trial
Official title:
Examining Written Disclosure as an Intervention for Posttraumatic Stress Disorder
This study will test the effectiveness of writing about a traumatic incident to treat post-traumatic stress disorder in people who have been in car accidents.
Post-traumatic stress disorder (PTSD) is a chronic and debilitating disorder caused by
experiencing a stressful or traumatic event. Although there is evidence that treatments for
PTSD are effective, many people do not seek treatment or seek treatment only after their PTSD
has become severe. This study will test a low-cost, brief, and easily implemented treatment
that may encourage people to seek treatment for PTSD. The treatment, called written
disclosure (WD), involves writing about the traumatic event that caused a person's PTSD. In
this study, people who have PTSD as the result of a motor vehicle accident will test two
versions of WD, one administered in a clinic and the other administered over the phone.
Participation in this study will last 5 weeks, with follow-up assessments continuing until 6
months after treatment. After screening, participants will be assigned to one of three
conditions: WD treatment delivered in the clinic, WD treatment delivered via phone, and
waitlist. The WD treatment involves five weekly writing sessions. During the first session,
trauma reactions and the rationale for WD will be explained to all participants, and then
participants will write for 30 minutes about their motor vehicle accident. The next four
sessions will involve only writing for 30 minutes. For those receiving treatment in the
clinic, a therapist will communicate directions and explanations to participants, and
participants will have their heart rate activity recorded continuously for 5 minutes prior to
writing and during the 30 minutes of writing. For those receiving treatment over the phone,
explanations of the study will be provided in writing, and a study staff member will call
participants before and after each writing session to ensure that participants understand the
directions and are not experiencing any unexpected negative reactions after writing.
Participants in the waitlist condition will not receive treatment for the first 4 months.
After that period, they will be offered the WD treatment.
Assessments of all participants will occur at baseline, after treatment, and 3 months after
treatment. Participants assigned to receive WD treatment, either in a clinic or via phone,
will also be assessed 6 months after treatment. Assessments administered at these points will
involve semi-structured clinical interviews, self-report questionnaires, and measures of
mood-related symptoms. Participants receiving treatment will also complete self-report
measurements of emotional response after each writing session and the Daily Experiences
Questionnaire every day during the 5 weeks of treatment. Participants on the waitlist will
also undergo assessments of suicidal thoughts and PTSD symptoms every 2 weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04317820 -
Deep Brain Reorienting in Post-traumatic Stress Disorder
|
N/A | |
Completed |
NCT05112003 -
Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot
|
N/A | |
Recruiting |
NCT04518267 -
Anger and Psychotrauma: Data From Military and Civilians
|
||
Completed |
NCT02502604 -
Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder
|
N/A | |
Terminated |
NCT02234687 -
A mGlu2/3 Agonist in the Treatment of PTSD
|
Phase 1 | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Completed |
NCT01738308 -
The Effects of Healing Touch on Post Operative Pediatric Patients
|
N/A | |
Terminated |
NCT02520726 -
PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims
|
Phase 4 | |
Completed |
NCT02213900 -
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
|
Phase 4 | |
Completed |
NCT01517711 -
Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)
|
Phase 4 | |
Completed |
NCT01437891 -
Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF)
|
N/A | |
Completed |
NCT01199107 -
Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD)
|
Phase 3 | |
Completed |
NCT01998100 -
Maximizing Treatment Outcome in Post-Traumatic Stress Disorder (PTSD)
|
Phase 3 | |
Completed |
NCT01231711 -
Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention
|
Phase 1 | |
Completed |
NCT00680524 -
Telephone-based Care for OEF/OIF Veterans With PTSD
|
N/A | |
Completed |
NCT00348036 -
Group Intervention for Interpersonal Trauma
|
N/A | |
Completed |
NCT00838006 -
Psychophysiologic Predictors of Post-deployment Mental Health Outcomes
|
N/A | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00158262 -
Effect of Propranolol on Preventing Posttraumatic Stress Disorder
|
Phase 4 | |
Completed |
NCT00183690 -
Prolonged Exposure Therapy Versus Active Psychotherapy in Treating Post-Traumatic Stress Disorder in Adolescents
|
Phase 1 |